In focus · trending topic

Testing Paradigm

1 stories · following the connections

Cancer Genetics, Inc. is Among the First To Drive New FDA-Approved Testing Paradigm for Non-Small Cell Lung Cancer Patients by Offering Thermo Fisher Scientific’s Oncomine Dx Target Test

By Nasdaq OMXNov 2, 2017, 11:30 AM UTC